Vertex Pharmaceuticals
VRTX
1,000 hedge funds and large institutions have $50.7B invested in Vertex Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 136 funds opening new positions, 433 increasing their positions, 313 reducing their positions, and 99 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 433 | Existing positions reduced: 313
37% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 99
7% more funds holding in top 10
Funds holding in top 10: 15 → 16 (+1)
3% more funds holding
Funds holding: 971 → 1,000 (+29)
0.98% less ownership
Funds ownership: 92.03% → 91.05% (-0.98%)
10% less call options, than puts
Call options by funds: $651M | Put options by funds: $722M
11% less capital invested
Capital invested by funds: $57B → $50.7B (-$6.31B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$308M |
| 2 |
ClearBridge Investments
New York
|
+$273M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$258M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$242M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$198M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$676M |
| 2 |
Jennison Associates
New York
|
-$666M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$653M |
| 4 |
Renaissance Technologies
New York
|
-$258M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$246M |
VRTX Hedge Fund Activity: Q1 2021 in Review
1,000 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2021, worth a combined $50.7B — down 11% from $57B a quarter earlier.
Buyers outnumbered sellers: 136 funds opened new VRTX positions and 99 closed out — a net gain of 37 holders — while 433 added to existing stakes and 313 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $308M. The largest seller was T. Rowe Price Associates, cutting an estimated $676M.
- 1,000 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2021, up from 971 in Q4 2020.
- Funds reported $50.7B of Vertex Pharmaceuticals stock for Q1 2021, down 11% quarter-over-quarter.
- 136 funds opened new Vertex Pharmaceuticals positions in Q1 2021 and 99 closed out, a net change of +37 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2021 was Avoro Capital Advisors, an estimated $308M added.
- The largest Vertex Pharmaceuticals seller in Q1 2021 was T. Rowe Price Associates, an estimated $676M sold.
Based on aggregated 13F filings for Q1 2021.